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Abstract
The International Mission on Prognosis and Analysis of Clinical Trials in Traumatic Brain Injury (IMPACT) and
Corticoid Randomisation After Significant Head injury (CRASH) prognostic models predict functional outcome after
moderate and severe traumatic brain injury (TBI). We aimed to assess their performance in a contemporary cohort of
patients across Europe. The Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury
(CENTER-TBI) core study is a prospective, observational cohort study in patients presenting with TBI and an indication
for brain computed tomography. The CENTER-TBI core cohort consists of 4509 TBI patients available for analyses from
59 centers in 18 countries across Europe and Israel. The IMPACT validation cohort included 1173 patients with GCS £12,
age ‡14, and 6-month Glasgow Outcome Scale-Extended (GOSE) available. The CRASH validation cohort contained
1742 patients with GCS £14, age ‡16, and 14-day mortality or 6-month GOSE available. Performance of the three
IMPACT and two CRASH model variants was assessed with discrimination (area under the receiver operating charac-
teristic curve; AUC) and calibration (comparison of observed vs. predicted outcome rates). For IMPACT, model dis-
crimination was good, with AUCs ranging between 0.77 and 0.85 in 1173 patients and between 0.80 and 0.88 in the
broader CRASH selection (n = 1742). For CRASH, AUCs ranged between 0.82 and 0.88 in 1742 patients and between
0.66 and 0.80 in the stricter IMPACT selection (n = 1173). Calibration of the IMPACT and CRASH models was generally
moderate, with calibration-in-the-large and calibration slopes ranging between -2.02 and 0.61 and between 0.48 and 1.39,
respectively. The IMPACT and CRASH models adequately identify patients at high risk for mortality or unfavorable
outcome, which supports their use in research settings and for benchmarking in the context of quality-of-care assessment.
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Introduction
Traumatic brain injury (TBI) is a heterogeneous diseasewith substantial variation in trauma mechanisms, pathophys-
iology, and clinical presentation.1 Early outcome prediction is
important in research settings (e.g., for selecting patients for clinical
trials).2 Informed predictions could also facilitate risk communica-
tion with patients or relatives and case-mix adjustment for bench-
marking quality of care.3 Many prognostic models for functional
outcome after moderate and severe TBI have been developed and
validated.4–6 Of these, the International Mission on Prognosis and
Analysis of Clinical Trials in Traumatic Brain Injury (IMPACT)
models and the Corticoid Randomisation After Significant Head
injury (CRASH) models are the most widely known.7,8
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These models were developed a decade ago on large, multi-
center cohorts using state-of-the-art statistical methodology. The
models combine clinical, radiological, and laboratory admis-
sion characteristics to predict risk of mortality and unfavorable
outcome. The IMPACT and CRASH models have shown highly
variable model performance across different settings.4 Moreover,
previous validation studies were mostly performed in small ob-
servational cohorts or randomized clinical trials (RCTs) that may
not represent the current TBI population. We aimed to gain insight
in the performance of the IMPACT and CRASH prognostic models
in contemporary patients across Europe.
Methods
IMPACT and CRASH models
Details of the development of the IMPACT and CRASH prog-
nostic models have been reported.7,8 In short, the IMPACT models
were developed on 8509 patients with moderate or severe TBI
(Glasgow Coma Scale [GCS] £12) from eight RCTs and three
observational studies.8 The IMPACT models comprise three vari-
ants (core, extended, and laboratory) with increasing complexity
(Table 1). The models predict mortality and functional outcome at 6
months post-injury.
The two versions of the CRASH prognostic model (basic and
computed tomography [CT]; Table 1) were developed on 10,008
TBI patients with GCS £14 from one RCT.7 The models predict
mortality at 14 days and functional outcome at 6 months post-injury.
Study design and population
We used data from the Collaborative European NeuroTrauma
Effectiveness Research in Traumatic Brain Injury (CENTER-TBI)
core study, a prospective, observational cohort study in patients
with TBI presenting within 24 h of injury and with an indication for
brain CT. Participants were recruited from December 2014 through
December 2017 from 59 centers in 18 countries across Europe and
Israel. The study protocol of CENTER-TBI has been described.9
Informed consent by patients and/or legal representative/next of kin
were obtained, according to local legislations, for all patients re-
cruited in the CENTER-TBI core dataset and documented in the
electronic case report form (e-CRF). Ethical approval was obtained
for each recruiting site. The sites, ethical committees, approval
numbers, and approval dates are listed on the website: https://www
.center-tbi.eu/project/ethical-approval.
Because the IMPACT and CRASH models were developed on
different selections of TBI patients, the models were validated on
separate cohorts with inclusion criteria corresponding to the de-
velopment cohorts. For the IMPACT core model, we included
patients ‡14 years of age with admission GCS £12 and available
functional outcome. The validation cohort for the CRASH basic
model included patients ‡16 years of age with admission GCS £14
and available functional outcome. For validation of the IMPACT
and CRASH models that included admission CT and laboratory
characteristics, patients without CT scan or blood samples in the
first 24 h after injury were excluded. To directly compare per-
formance of the IMPACT and CRASH models, we additionally
validated the IMPACT models in the CRASH validation cohort
and vice versa.
In CENTER-TBI, functional outcome at 6 months post-injury
was assessed with the Glasgow Outcome Scale-Extended (GOSE).
In line with the original IMPACT and CRASH models, we di-
chotomized the 6-month GOSE into mortality (GOSE 1) versus
survival (GOSE 2–8), and unfavorable (GOSE 1–4) versus favor-
able (GOSE 5–8) outcome. For the CRASH models, mortality was
assessed at 14 days post-injury.
Predictor effects
Definitions and coding of the predictors in the validation cohorts
were similar to those in the IMPACT and CRASH development
cohorts (Supplementary Tables S1–S3).7,8 Major extracranial in-
jury was defined as a score of ‡3 on at least one of the extracranial
domains of the Abbreviated Injury Scale.10
The IMPACT and CRASH logistic regression models were re-
fitted in the validation data to enable comparison of predictor ef-
fects between development and validation cohorts. Associations
between predictors and outcomes were expressed as odds ratios
(ORs) with 95% confidence intervals (CIs).
Validation
The IMPACT and CRASH models were validated by applying
the coefficients of the original models to the validation data (Sup-
plementary Tables S2 and S3). Because participating centers in
CENTER-TBI were mainly situated in Western countries, we used
the CRASH models for high-income countries.7 Model perfor-
mance was assessed with discrimination and calibration. Dis-
crimination was expressed with the area under the receiver
operating characteristic curve (AUC). The AUC ranges from 0.5
for a non-discriminative model to 1.0 for a perfect model.11 Cali-
bration indicates the agreement between predicted and observed
outcome probabilities. It was assessed graphically by plotting ob-
served frequencies of mortality and unfavorable outcome versus
predicted risk. Additionally, we calculated the calibration slope and
calibration-in-the-large. The calibration slope is ideally equal to 1
and represents the overall predictor effects in the validation cohort
versus the development cohort. Calibration-in-the-large indicates
whether predictions are systematically too high or too low, and
should ideally be zero.12
Model discrimination at external validation may be affected
by the distribution of patient characteristics (case mix) in the
validation cohort.13,14 Distinguishing patients with good versus
Table 1. Variables Included in the International Mission on Prognosis and Analysis of Clinical Trials (IMPACT)
and Corticoid Randomisation after Significant Head Injury (CRASH) Prognostic Models
IMPACT core IMPACT extended IMPACT laboratory CRASH basic CRASH CT
Age Core model predictors + Extended model predictors + Age Basic model predictors +
GCS motor score Hypoxia Glucose GCS total score Petechial hemorrhages
Pupillary reactivity Hypotension Hemoglobin Pupillary reactivity Obliteration of third
ventricle or basal
cisterns
Marshall CT classification Major extracranial injury
tSAH
tSAHEDH
Midline shift >5 mm
Non-evacuated hematoma
GCS, Glasgow Coma Scale; CT, computed tomography; tSAH, traumatic subarachnoid hemorrhage; EDH, epidural hematoma.















































poor outcome is more difficult in a homogeneous cohort than in a
heterogeneous population, leading to higher AUCs in heteroge-
neous cohorts. We therefore calculated the case-mix–corrected
AUC, which reflects model discrimination under the assumption
that the regression coefficients are correct for the validation
population.14
Statistical analysis
Statistical analyses were performed with R software (version
3.4.3; R Foundation for Statistical Computing, Vienna, Austria).
Calibration plots were created with an updated version of the
val.prob function (rms library in R).15 Missing 6-month GOSE as a
consequence of loss to follow-up (in patients with at least one
GOSE observation at another time point) were imputed with a
Bayesian mixed-effect model (Supplementary Table S3). Patients
without any GOSE observation were excluded from the analyses.
Derived variables for GCS (motor) score and pupillary reactivity
were generated based on methodology as used in the IMPACT
database (Supplementary Table S3).16 The remaining missing
predictor values were statistically imputed with multiple imputa-
tion based on the predictors and outcomes included in the IMPACT
and CRASH models (mice package in R). CENTER-TBI data were
collected through the Quesgen e-CRF (Quesgen Systems Inc,
Burlingame, CA), hosted on the International Neuroinformatics
Coordinating Facility (INCF) platform and extracted by the INCF
Neurobot tool (INCF, Sweden). Version Core 1.1 of the CENTER-
TBI dataset was used in this study.
Results
Study population
In total, 4509 patients included in the CENTER-TBI core study
could be analyzed. Of those, 1173 and 1742 patients met the in-
clusion criteria for the IMPACT and CRASH validation cohort,
respectively (Supplementary Fig. S1). Missing predictor values for
the IMPACT (5%) and CRASH (4%) cohorts were imputed
(Supplementary Table S4).
The IMPACT validation cohort consisted mainly of severe TBI
patients (72%). At 6 months, 347 patients had died (30%), and 644
patients (55%) had unfavorable outcomes (Table 2). In the CRASH
validation cohort, one third of the patients had an admission GCS of
13–14. At 14 days, 266 patients had died (15%), and at 6 months,
751 patients (43%) had unfavorable outcomes (Table 2).
Compared to the IMPACT and CRASH development cohorts,
patients in the CENTER-TBI validation cohorts were, on aver-
age, 20 years older and had more-severe TBI (Table 2). More
patients had major extracranial injury in the CRASH validation
cohort (49%) than the development cohort (22%). Traumatic
subarachnoid hemorrhage occurred almost twice as often in the
CENTER-TBI validation cohorts versus the IMPACT and
CRASH development cohorts. Overall, functional outcomes at 6
months were poorer in CENTER-TBI, with a higher proportion
of unfavorable outcomes in both validation cohorts compared to
the development cohorts (Table 2).
IMPACT models
In CENTER-TBI, associations of the predictors in the IMPACT
models with 6-month outcome were similar to those reported for
the IMPACT development cohort (Supplementary Table S5).
However, presence of hypoxia and traumatic subarachnoid hem-
orrhage did not significantly increase risk of poor outcome in the
CENTER-TBI cohort. The IMPACT models distinguished well
between patients who died and patients who were alive, indicated
by AUCs >0.80 (Table 3). Addition of CT variables to the core
model for mortality increased discriminative ability (AUC 0.81 for
the core model vs. 0.85 for the extended model; Table 3).
The IMPACT laboratory model for mortality also had an AUC
of 0.85 (Table 3). The IMPACT models had slightly lower dis-
criminative ability for unfavorable outcome (AUC core, 0.77; ex-
tended, 0.80; laboratory, 0.81; Table 3).
Calibration showed that observed mortality risk was lower than
predicted (Supplementary Table S6; Fig. 1) and the IMPACT
models slightly over- (core and extended) or underestimated (lab-
oratory) risks for unfavorable outcome (Supplementary Table S6;
Fig. 1). Calibration slopes ranged between 1.20 and 1.32 for the
models for mortality and between 0.97 and 1.02 for the models for
unfavorable outcome (Supplementary Table S6; Fig. 1), reflecting
stronger (mortality) or similar (unfavorable outcome) predictor
effects in CENTER-TBI versus the IMPACT development cohort.
We observed higher AUCs for the IMPACT models for mortality
in the validation cohort compared to the development cohort (e.g.,
for the laboratory model: AUC 0.85 vs. 0.79, respectively; Table 3).
When calculating the case-mix–corrected AUC, these differences in
discriminative ability disappeared (Table 3). For the models for
unfavorable outcome, the AUC at external validation and the case-
mix–corrected AUC were similar, indicating comparable case mix.
CRASH models
Associations between some predictors and outcomes varied
between the CENTER-TBI validation cohort versus the CRASH
development cohort. For instance, presence of major extracra-
nial injury did not significantly increase mortality risk in
CENTER-TBI, and the effect of midline shift was non-significant
(Supplementary Table S7).
Discriminative ability of the CRASH models was good for both
mortality and unfavorable outcome (Table 3). We observed com-
parable AUCs for the CT model (0.88 for mortality and 0.84 for
unfavorable outcome; Table 3) versus the basic model (0.86 for
mortality and 0.82 for unfavorable outcome; Table 3).
Assessment of model calibration revealed differences between
observed and predicted risk of mortality and unfavorable outcome
for the CRASH CT model (Supplementary Table S6; Fig. 2). The
CRASH basic model adequately predicted mortality and unfa-
vorable outcome, whereas the CT model strongly overestimated
risk of mortality and unfavorable outcome (Supplementary
Table S6; Fig. 2). The moderate calibration slopes for the CRASH
CT model reflect the smaller predictor effects in CENTER-TBI
compared to the CRASH development cohort (Supplementary
Table S6; Fig. 2).
Discriminative ability was similar in the validation versus de-
velopment cohort, although the validation cohort had a somewhat
more homogeneous case mix (Table 3).
Comparison IMPACT and CRASH
When validating the IMPACT models in the broader CRASH
selection in CENTER-TBI (n = 1742), performance of the IMPACT
and CRASH models for mortality and unfavorable outcome was
similar (Supplementary Table S8; Supplementary Fig. S2).
Validation of the CRASH models in the stricter IMPACT se-
lection within CENTER-TBI (n = 1173) yielded lower AUCs and
larger discrepancies between observed and predicted rates of
mortality and unfavorable outcome for the CRASH models com-
pared to the IMPACT models (Supplementary Table S8; Supple-
mentary Fig. S3).
















































We performed detailed evaluations of the external validity of the
IMPACT and CRASH prognostic models in a large contemporary
European cohort of TBI patients. Both sets of models showed good
discriminative ability, which modestly improved with addition of
CT variables to the IMPACT core and CRASH basic models. There
were substantial differences between observed and predicted out-
come risk, specifically for the CRASH CT model.
Over the past decade, the IMPACT and CRASH models have
been externally validated in many different, but mostly small, se-
lected or single-country cohorts. A recent systematic review on
prognostic models in moderate and severe TBI showed that dis-
criminative ability of the IMPACT and CRASH models at external
validation was moderate to good across different settings (mean
AUCs weighted for sample size, 0.77–0.82 over 91 validations).4
Calibration was, however, highly variable and substantial mis-
calibration was observed in subgroups of TBI patients (e.g., pa-
tients who underwent decompressive craniectomy). Compared to
previous external validation studies, the IMPACT and CRASH
models performed generally well in the CENTER-TBI validation
cohort, indicating that the models stood the test of time.4 Overall,
Table 2. Characteristics of Patients in the International Mission on Prognosis and Analysis of Clinical Trials
(IMPACT) and Corticoid Randomisation after Significant Head Injury (CRASH) Development Cohorts
and the IMPACT and CRASH Validation Cohorts in the Collaborative European NeuroTrauma Effectiveness
Research in Traumatic Brain Injury (CENTER-TBI) Core Study
Admission characteristics Measure or category
IMPACT
development











cohort (n = 1742)
Age, years Median (IQR) 30 (21–45) 49 (29–66) 33 (23–47) 51 (32–67)
GCS motor score None (1) 1395 (16%) 527 (45%) — —
Extension (2) 1042 (12%) 66 (6%) — —
Abnormal flexion (3) 1085 (13%) 67 (6%) — —
Normal flexion (4) 1940 (23%) 118 (10%) — —
Localizes/obeys (5/6) 2591 (30%) 395 (34%) — —
Untestable/missing (9) 456 (5%) 0 (0%) — —
GCS total score (3–14) Mild (13–14) — — 3019 (30%) 582 (33%)
Moderate (9–12) — 324 (28%) 3041 (30%) 316 (18%)
Severe (3–8) — 849 (72%) 3948 (40%) 844 (48%)
Pupillary reactivity Both pupils reacted 4486 (53%) 817 (71%) 8057 (81%) 1338 (77)
One pupil reacted 886 (10%) 99 (8%) 588 (6%) 111 (6%)
No pupil reacted 1754 (21%) 216 (18%) 825 (8%) 228 (13%)
Major extracranial injury Yes — — 2216 (22%) 845 (49%)
Hypoxia Yes or suspected 1116 (13%) 198 (17%) — —
Hypotension Yes or suspected 1171 (14%) 187 (16%) — —
Marshall CT classification I 360 (4%) 66 (6%) — —
II 1838 (22%) 413 (35%) — —
III/IV 1050 (12%) 124 (11%) — —
V/VI 1944 (23%) 377 (32%) — —
Traumatic subarachnoid
hemorrhage
Yes 3313 (39%) 764 (65%) 2458 (25%) 1009 (58%)
Epidural hematoma Yes 999 (12%) 170 (14%) — —
‡1 petechial hemorrhages Yes — — 2238 (22%) 215 (12%)
Obliteration of third ventricle
or basal cisterns
Yes — — 1827 (18%) 474 (27%)
Midline shift >5 mm Yes — — 1136 (11%) 347 (20%)
Non-evacuated hematoma Yes — — 2111 (21%) 480 (28%)
Glucose (mmol/l) Median (IQR) 8.2 (6.7–10.4) 7.8 (6.5–9.6) — —
Hemoglobin (g/dL) Median (IQR) 12.7 (10.8–14.3) 13.0 (11.3–14.2) — —
Mortality at 14 days Yes — — 1948 (19%) 266 (15%)
Outcome at 6 months Dead 2396 (28%) 347 (30%) 2323 (23%) 394 (23%)
Vegetativea 351 (4%) 0 (0%) 272 (3%) 0 (0%)
Lower severe disability — 243 (21%) — 291 (17%)
Upper severe disability 1335 (16%) 54 (5%) 962 (10%) 66 (4%)
Lower moderate disability — 91 (8%) — 138 (8%)
Upper moderate disability 1666 (20%) 148 (13%) 1664 (17%) 212 (12%)
Lower good recovery — 147 (13%) — 267 (15%)
Upper good recovery 2761 (32%) 143 (12%) 4333 (43%) 374 (22%)
Death or severe disability 4082 (48%) 644 (55%) 3557 (36%) 751 (43%)
aVegetative state and lower severe disability combined (GOSE categories 2 and 3). IMPACT, International Mission on Prognosis and Analysis of
Clinical Trials; CRASH, Corticoid Randomisation After Significant Head injury; CENTER-TBI, Collaborative European NeuroTrauma Effectiveness
Research in Traumatic Brain Injury; IQR, interquartile range; GCS, Glasgow Coma Scale; CT, computed tomography.















































observed mortality was lower than predicted, and observed unfa-
vorable outcome was similar as predicted, which may indicate that
survival has improved over time, but more patients survive with
(severe) disabilities.
Our validation cohort was part of a large and unique multi-center
observational study with data from contemporary TBI patients
throughout Europe.9 We could validate the original IMPACT and
CRASH models because of availability of all included predictors
and outcomes. However, discrepancies might still exist in the as-
sessment method and definitions of predictors and outcomes. For
example, imaging techniques may have improved or changed over
time.13 Another limitation of our study is that the CRASH models
for low- to middle-income countries could not be validated because
mainly high-income countries participated in CENTER-TBI.
Model performance at external validation is sensitive to several
study characteristics.13 Differences in case mix in the validation
cohorts compared to the development cohorts influenced the dis-
criminative ability of the IMPACT and CRASH models. The
CENTER-TBI validation cohort generally consisted of older and
more severely affected TBI patients and was more heterogeneous
than the IMPACT database, which predominantly included
RCTs.8,16 The CENTER-TBI cohort was somewhat more homo-
geneous than the CRASH trial, which fits with the relatively broad
inclusion criteria in that trial.17 We observed substantial mis-
calibration for the IMPACT and CRASH models in CENTER-TBI.
This could be explained by differences in prevalence and effects of
predictors between the derivation and validation cohorts. Major
extracranial injury, traumatic subarachnoid hemorrhage, and mid-
line shift were more prevalent in CENTER-TBI than in the CRASH
development cohort, whereas mortality at 14 days was similar
(Table 2). Presence of midline shift was not associated with mor-
tality and unfavorable outcome in CENTER-TBI (Supplementary
Table S7). This may explain the substantial overestimation of
mortality and unfavorable outcome by the CRASH CT model.14
Overall, discriminative ability of the IMPACT and CRASH
models only marginally improved with increasing model com-
plexity. This observation confirms that the core clinical predictors
(age, GCS [motor], score, and pupillary reactivity) are essential for
adequate identification of TBI patients at high risk of mortality or
unfavorable outcome, and that additional predictors add relatively
little prognostic information. Calibration of the IMPACT core
models was similar or inferior compared to the more-complex
models (Supplementary Table S6; Fig. 1). This underscores the
need for model updating (e.g., refitting the model intercept or re-
fitting the coefficients) to adjust models to specific clinical set-
tings.11,18 Extension of the IMPACT and CRASH models with new
predictors has been attempted previously, but did not yield sub-
stantial improvement in model performance.4 In CENTER-TBI,
updating the IMPACT (and CRASH) models may be pursued.19,20
For instance, performance of the IMPACT extended model may be
improved by replacing the Marshall CT classification with a more-
recent CT score (e.g., Rotterdam or Helsinki) or a combination of
Table 3. Discriminative Ability of the International Mission on Prognosis and Analysis of Clinical Trials (IMPACT)
and Corticoid Randomisation after Significant Head Injury (CRASH) Models in the Collaborative European















0.77 0.81 0.79 0.86 0.88
AUC, external validation 0.81 (0.79–0.84) 0.85 (0.82–0.87) 0.85 (0.82–0.87) 0.86 (0.83–0.88) 0.88 (0.86–0.90)















0.78 0.81 0.81 0.81 0.83
AUC, external validation 0.77 (0.74–0.80) 0.80 (0.78–0.83) 0.81 (0.78–0.84) 0.82 (0.80–0.84) 0.84 (0.82–0.86)
AUC, case-mix corrected 0.78 (0.74–0.79) 0.80 (0.79–0.84) 0.81 (0.78–0.84) 0.83 (0.81–0.85) 0.86 (0.84–0.88)
All performance values for external validation are reported with a 95% confidence interval. IMPACT, International Mission on Prognosis and Analysis
of Clinical Trials; CRASH, Corticoid Randomisation After Significant Head injury; CT, computed tomography; AUC, area under the receiver operating
characteristic curve.
‰
FIG. 1. Calibration plots of the International Mission on Prognosis and Analysis of Clinical Trials (IMPACT) models for (A) mor-
tality and (B) unfavorable outcome at 6 months. Predicted probabilities are on the x-axis and observed outcomes on the y-axis. The
distribution of the predicted probabilities is shown at the bottom of the graphs, separate for those with ( = 1) and without ( = 0) the
outcome of interest. The 45-degree line with intercept 0 and slope 1 represents perfect agreement between predicted and observed
outcome rates. Deviation above or below this line indicates that the model under- or overestimates mortality or unfavorable outcome
rates, respectively. For instance, the calibration plots in (A) show that all three IMPACT models tend to overestimate mortality rates in
the CENTER-TBI validation cohort. CENTER-TBI, Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain
Injury.






























































































individual CT characteristics.21,22 Also, the models could be en-
riched with promising biomarkers or dynamic characteristics ob-
tained during the clinical course.23
Continuous external validation of prognostic models for mod-
erate and severe TBI in recent cohorts has been recommended.4,23,24
The IMPACT and CRASH models were developed on relatively
historic data, whereas the epidemiology of TBI has changed
substantially over the last years (e.g., regarding age distribution).1
This study adds to the existing evidence by showing that the
IMPACT and CRASH models are valid for outcome prediction in
contemporary TBI patients across Europe. Nevertheless, dis-
crepancies between observed and predicted rates of mortality and
unfavorable outcome exist for both sets of models. Adjustment of
the models to local hospital and patient characteristics is therefore
strongly recommended.
Performance of the IMPACT and CRASH models in the
broadest selection of TBI patients was comparable. The additional
effect of major extracranial injury in CRASH seems limited,
FIG. 2. Calibration plots of the Corticoid Randomisation After Significant Head injury (CRASH) models for (A) mortality at 14 days
and (B) unfavorable outcome at 6 months. Predicted probabilities are on the x-axis and observed outcomes on the y-axis. The
distribution of the predicted probabilities is shown at the bottom of the graphs, separate for those with ( = 1) and without ( = 0) the
outcome of interest. The 45-degree line with intercept 0 and slope 1 represents perfect agreement between predicted and observed
outcome rates. Deviation above or below this line indicates that the model under- or overestimates mortality or unfavorable outcome
rates, respectively. For instance, the CRASH CT model overestimates mortality and unfavorable outcome rates in the CENTER-TBI
validation cohort. CT, computed tomography; CENTER-TBI, Collaborative European NeuroTrauma Effectiveness Research in Trau-
matic Brain Injury.















































probably because patients in CENTER-TBI were selected based on
TBI and not any trauma.10 The decision on which model to use
should mainly be guided by the characteristics of a specific setting
or population (e.g., TBI severity, country economic status). Use of
either the IMPACT or CRASH model and degree of complexity of
the model also depends on availability of predictors. Given that the
substantial uncertainty on likely outcomes in individual patients,
the IMPACT and CRASH models are not recommended for clinical
decision making. Treatment options for TBI patients are scarce, and
documenting prognosis in the intensive care setting does not seem
to substantially affect treatment decisions.25–27
On the other hand, there is an increasing recognition that estimates
of prognosis by clinicians are often unduly pessimistic for TBI pa-
tients,28 and regular comparison of outcome predicted by these
models with clinical expectations may help individual clinicians
calibrate their prognostication and practice. Based on the good dis-
criminative ability of the IMPACT and CRASH models, potential
applications in research settings are risk stratification in trials and
covariate adjustment in statistical analyses to increase statistical
power. The models may also provide a point of reference for quality
of care by comparing observed versus expected outcomes.3
Conclusions
The IMPACT and CRASH models adequately identify patients
at high risk for mortality or unfavorable outcome, which supports
their use in research settings and for benchmarking in the context of
quality-of-care assessment.
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Erzsébet Ezer,49 Martin Fabricius,50 Valery L. Feigin,51 Kelly Foks,52
Shirin Frisvold,53 Alex Furmanov,54 Pablo Gagliardo,55 Damien
Galanaud,16 Dashiell Gantner,28 Guoyi Gao,56 Pradeep George,57
Alexandre Ghuysen,58 Lelde Giga,59 Ben Glocker,60 Jagoš Golu-
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59Neurosurgery clinic, Pauls Stradins Clinical University Hos-
pital, Riga, Latvia
60Department of Computing, Imperial College London, London,
United Kingdom
61Department of Neurosurgery, Hospital Universitario 12 de
Octubre, Madrid, Spain
62Department of Anesthesia, Critical Care and Pain Medicine,
Medical University of Vienna, Vienna, Austria
63College of Health and Medicine, Australian National Uni-
versity, Canberra, Australia
64Department of Neurosurgery, Neurosciences Centre & JPN
Apex Trauma Centre, All India Institute of Medical Sciences, New
Delhi, India
65Department of Neurosurgery, Erasmus MC, Rotterdam, The
Netherlands
66Department of Neurosurgery, Oslo University Hospital, Oslo,
Norway















































67Division of Psychology, University of Stirling, Stirling, United
Kingdom
68Division of Neurosurgery, Department of Clinical Neu-
rosciences, Addenbrooke’s Hospital & University of Cambridge,
Cambridge, United Kingdom
69Department of Neurology, University of Groningen, Uni-
versity Medical Center Groningen, Groningen, The Netherlands
70Neurointensive Care, Sheffield Teaching Hospitals NHS
Foundation Trust, Sheffield, United Kingdom
71Department of Intensive Care and Department of Ethics and
Philosophy of Medicine, Erasmus Medical Center, Rotterdam, The
Netherlands
72Department of Clinical Neuroscience, Neurosurgery, Umeå
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Hungary
120Division of Neuroscience Critical Care, John Hopkins Uni-
versity School of Medicine, Baltimore, USA
121Department of Neuropathology, Queen Elizabeth University
Hospital and University of Glasgow, Glasgow, UK
122Dept. of Department of Biomedical Data Sciences, Leiden
University Medical Center, Leiden, The Netherlands















































123Department of Pathophysiology and Transplantation, Milan
University, and Neuroscience ICU, Fondazione IRCCS Cà Granda
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